HistoGeneX

HistoGeneX, a laboratory group established in 2001, supports pharmaceutical and biotechnology companies in developing, approving, and monitoring new anti-cancer drugs through the development and implementation of biomarker tests. Biomarkers are specific genes, proteins, or other molecular variations that can be detected in tissue and blood samples from patients.

Through biomarker tests conducted as part of clinical studies, HistoGeneX helps demonstrate which patients are more or less likely to benefit from a drug (personalised medicine). This approach prevents the prescription of expensive anti-cancer drugs to patients for whom it can be determined in advance that the drug will not be effective. The application of biomarker research in clinical studies therefore helps to personalise therapy and improve the quality of life of patients; it enables pharmaceutical companies to better focus their R&D efforts and is encouraged by governments seeking to manage their ever-increasing social security spending more efficiently.